| 0.965 -0.003 (-0.27%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.77 | 1-year : | 2.26 |
| Resists | First : | 1.51 | Second : | 1.94 |
| Pivot price | 1.09  |
|||
| Supports | First : | 0.83 | Second : | 0.69 |
| MAs | MA(5) : | 0.96 |
MA(20) : | 1.23 |
| MA(100) : | 1.62 |
MA(250) : | 4.96 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 15.1 |
D(3) : | 14.6 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 11.19 | Low : | 0.83 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NTBL ] has closed above bottom band by 31.3%. Bollinger Bands are 17.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.07 - 1.08 | 1.08 - 1.08 |
| Low: | 0.94 - 0.94 | 0.94 - 0.95 |
| Close: | 0.96 - 0.96 | 0.96 - 0.97 |
Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and thus fast-track clinical development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor for acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes indications; and Fosciclopirox, a pro-drug of ciclopirox for AML. Notable Labs, Ltd. is headquartered in Foster City, California.
Fri, 19 Apr 2024
Notable Labs (NTBL) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Sat, 13 Apr 2024
Smaller Reporting Status for Notable Labs: Navigating Investor Concerns Amidst Scaled-Down Disclosure - TipRanks ... - TipRanks
Fri, 12 Apr 2024
Notable Labs Reports 2023 Financial Results and Provides a Business Update - GlobeNewswire
Tue, 09 Apr 2024
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory ... - Yahoo Finance
Mon, 08 Apr 2024
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay at ... - GlobeNewswire
Tue, 05 Mar 2024
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -10 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 9.02e+006 (%) |
| Held by Institutions | 99470 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -3.42 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 341.4 % |
| Return on Equity (ttm) | -73.2 % |
| Qtrly Rev. Growth | 310000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.44e+007 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -0.29 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 21240 |
| Forward Dividend | 64540 |
| Dividend Yield | 2201040% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|